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This article was written is response to a request from the editor-in-chief as a result of my receiving the Governor’s Award in
Scientific Awareness. My goal is to provide a glimpse into a 40 plus year research career that was predominately focused on
the role of thromboxane A2 and its receptor (TP) in physiologic and pathophysiologic processes in the cardiovascular system.
It also enumerates the lessons learned along the way that may lead to a productive research career. Those lessons were:
perseverance; think out of the box; challenge the dogma; take risks; failure is not a bad thing; focus; select a good mentor(s);
choose your collaborators and colleagues wisely (team science); when you start an experiment-finish it (analyze all the data);
and take time for your family.
This review is written in response to a request from the editor-inchief as a result of my receiving the Governor’s Award for
Excellence in Scientific Awareness. The following was adopted
from the Keynote Address for the 50th Annual Perry V. Halushka
MUSC Research day given on November 12, 2015.
The themes for my address were; lessons learned, team science
and translational research. These 3 themes reflect the story of my
career in research and contributed to receiving the Governor’s
award. The focus of my research has been on the cardiovascular
system and the role that thromboxane A2 plays in both
physiologic and pathophysiologic processes.
Metabolism of Arachidonic Acid
In order to appreciate the role of thromboxane A2 in physiologic
and pathophysiologic processes, one needs to have a basic
understanding of the formation of thromboxane A2 from
arachidonic acid. Arachidonic acid is an essential fatty acid that
cannot be synthesized by the mammalian species (Figure 1). It is
acquired from various food sources and is stored in membrane
phospholipids and released upon activation of phospholipase A2.
Once released it is rapidly metabolized to the labile
endoperoxides, PGG2 and PGH2 via the enzyme fatty acid
cyclooxygenase. The enzyme is inhibited by aspirin and nonsteroidal anti-inflammatory drugs. PGH2 is rapidly metabolized
by thromboxane synthase to thromboxane A2, which is very labile
with a t1/2 of ~30 seconds. It is hydrolyzed to the stable but
inactive thromboxane B2. Thromboxane synthase is inhibited by
imidazole and other derivatives of imidazole. Thromboxane A2
stimulates platelets to aggregate and vascular smooth muscle cells
to contract. Thus, thromboxane A2 participates in hemostatic
control of bleeding as part of a normal physiologic process.
However, for example, in the setting of atherosclerotic
cardiovascular disease thromboxane A2 plays a pathophysiologic
role in vascular occlusive phenomena. It is aspirin’s ability to
irreversibly inhibit the platelet cyclooxygenase and thus
thromboxane A2 that leads to its beneficial effects in the primary
and secondary prevention of heart attacks and strokes.
Endotoxemia, Thromboxane A2 and TP Receptors
Around 1979, James Cook, PhD and Curtis Wise, PhD brought to
my attention their observation that essential fatty acid deficient
rats (EFAD) were resistant to the lethal effects of endotoxin.
Endotoxin is the outer wall of gram negative bacteria and is
released when the bacteria are killed. Endotoxin causes a host
reaction which in turn can lead to severe shock and death. This
situation is mostly commonly encountered when individuals have
overwhelming bacterial infections in their blood stream. As

Figure 1. Metabolism of arachidonic acid.
Aspirin,
indomethacin and other non-steroidal anti-inflammatory drugs
(NSAIDS) inhibit the enzyme, fatty acid cyclooxygenase.
Imidazole and derivatives of imidazole inhibit thromboxane
synthase. Thromboxane A2 stimulates platelets to aggregate
and smooth muscle cells to contract.
noted above, thromboxane A2 is a fatty acid derived from the
essential fatty acid arachidonic acid (Figure 1).
Our hypothesis was that endotoxin stimulates the formation of
thromboxane A2 and that it contributes to the pathophysiology of
endotoxic shock. We postulated that the EFAD rats could not
make thromboxane A2 and therefore were protected from the
lethal effects of endotoxin. To test the hypothesis several series
of experiments were conducted; 1) measurement of plasma levels
of thromboxane B2 in control and endotoxin treated rats, 2)
inhibition of the metabolism of arachidonic acid at the level of
the cyclooxygenase using indomethacin, 3) at the level of
thromboxane synthase using imidazole and 4) direct antagonism
of the thromboxane (TP) receptor using 13- azaprostanoic acid.
Endotoxin significantly increased the levels of plasma
thromboxane B2 in the rats challenged with endotoxin compared
to the EFAD rats and the imidazole treated rats (Figure 2) (1).
Treatment with either indomethacin or imidazole significantly
improved survival of the rats treated with endotoxin (Table 1)
(1).
Ibuprofen also significantly improved the outcome of
endotoxic shock in rats (2). Treatment of the endotoxic rats with
13-azaprostanoic acid also significantly improved survival
compared to the vehicle treated group (1). Working with Dr.
David Reines, a surgeon/intensive care physician, we
subsequently went on to show that patients that died from
overwhelming sepsis had a 10 fold greater level of plasma
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Figure 2. Plasma levels of thromboxane B2 following a
bolus injection of endotoxin in rats. The levels of
thromboxane B2 were significantly (p<0.01) greater in
the control rats compared to those treated with
indomethacin or imidazole. N=8 to 10/group. Modified
from J. Clinical Investigation 65:227, 1981, J. Cook et
al.
Table 1. Survival rates after a lethal injection of endotoxin in rats.
Time after endotoxin (hrs)
Group (Dead/Total)
Control
EFAD (7-8 wk old)
EFAD (12-13 wk old)
Indomethacin I.V.
Imidazole I.V.

5
14/20
0/12
0/14
0/8
1/10

12
19/20
1/12
0/14
0/8
2/10

24
19/20
7/12
0/14
1/8
4/10

48
19/20
8/12
0/14
1/8
4/10

thromboxane B2 compare to those that survived a bout of sepsis
or patients in the ICU that did not have a bout of septic shock (3).
We also treated a group of septic patients with a thromboxane
synthase inhibitor and showed that it was safe and effective in
lowering plasma thromboxane B2 levels (4). The company that
made the thromboxane synthase inhibitor decided not to further
develop it, so we were not able to conduct a large multicenter
clinical trial to test its efficacy as a treatment for septic shock.
The company along with several other companies may have
decided to drop the development of thromboxane synthase
inhibitors as antiplatelet agents based on the observations made
by one of my graduate students (see below).
Lessons learned: Choose your collaborators and colleagues
wisely (Team Science) (Dr. Cook and I have shared an RO1 for
33 years.) and think out of the box.
Platelet Thromboxane Formation and Platelet Aggregation
Dr. John Colwell, a diabetologist at MUSC, found that diabetic
patients’ platelets were more sensitive to aggregating agents
compared to the appropriate controls (5). Given the role of
thromboxane A2 in promoting platelet aggregation, we
collaborated to determine the formation of thromboxane A2 by
platelets from diabetic and control subjects. We found that
diabetic patients’ platelets made significantly more thromboxane
A2 and at a significantly greater rate compared to the control
subjects’ platelets (6). In collaboration with Ron Mayfield, also a
diabetologist, we found that improving glucose control in the
diabetic patients decreased the formation of thromboxane A2 by
their platelets (7).

In the late 70s there was a reigning hypothesis that platelet
thromboxane A2 synthesis was a major contributor to platelet
aggregation and that inhibition of its synthesis would confer
significant inhibition of platelet aggregation. Along with a couple
of my colleagues, we decided to synthesize a series of
thromboxane synthase inhibitors as potential drugs to act as
inhibitors of platelet aggregation. 7-IHA was one of those
compounds. We asked Linda Grimm a graduate student at the
time to test its antiplatelet effects and its ability to inhibit
thromboxane A2 synthesis. Soon after she finished the first
experiment assessing arachidonic acid induced platelet
aggregation, she came to my office and concluded that 7-IHA did
not inhibit thromboxane A2 synthesis because it did not inhibit
arachidonic acid induced platelet aggregation. I asked her if she
had measured thromboxane B2. She said that she had not. So I
told her to come back to me once she had measured thromboxane
B2. Much to her amazement, 7-IHA significantly inhibited
thromboxane synthesis, yet did not inhibit platelet aggregation.
Her results completely disproved the reigning hypothesis. The
saga continues because, when we submitted the paper for
publication, the review came back with a rejection and my take
on the review was that it was pejorative and written by the person
who was promulgating the hypothesis. I appealed to the editor
and he agreed to have the manuscript reviewed by different
reviewers. Within about 2 weeks, the manuscript came back
accepted as is (8).
Lessons learned: When you start an experiment, finish it with a
complete analysis of the data, challenge the dogma and
perseverance.
“When you come to a fork in the road, take it”, Yogi Berra
We had conducted many studies demonstrating a role for
thromboxane A2 in physiologic and pathophysiologic processes
and decided that it was time to start to characterize the binding
characteristics of thromboxane A2 (TP) receptors and their
signaling mechanisms. However, there were no radioactive
ligands available that could be used for characterization of the
binding characteristics and regulation of their expression. So
along with our chemistry colleagues, we synthesized a compound
13-cisAPO, a derivative of 13-azaprostanoic acid, that could be
radiolabelled with 125I using a simple one-step process. With the
compound in hand, we took a 1 year sabbatical in London,
England to work with Dr. John MacDermot, to begin to
characterize the binding characteristics of the TP receptor using
125Iodo-cisAPO. Little did we know that we would run into many
challenges, the most critical one was that 125Iodo-cisAPO had a
very low affinity for the receptor, making it very difficult to get
specific binding to the platelet TP receptor. Nonetheless, with
John MacDermot’s guidance, we persevered and were able to
ultimately demonstrate specific binding (9) and establish the
concept of making 125I labeled ligands for the characterization of
TP receptors (10-12).
Lessons learned: Think out of the box, Choose your
collaborators and colleagues wisely, Failure is not a bad thing,
Take risks, Focus and Perseverance.
Characterization of the TP Receptors
With a generous gift of a chemical precursor from the ONO
pharmaceutical company, Dale Mais, a postdoctoral fellow, and
ultimately assistant professor, synthesized a series of
thromboxane receptor antagonists. Using these compounds, we
characterized the TP receptor in platelets and blood vessels and
demonstrated that they represented two distinct classes of
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receptors (13-15). The receptor was cloned by Narumyia et al,
and since they could not find a second transcript, they concluded
that there was only one class of receptors (16). However, a splice
variant was subsequently discovered (17) and we also generated
additional data to support the notion that there were two classes
of receptors (18, 19).
Lessons learned: Believe in your data based on first principles.
The final vignette deals with the earlier observations that some
young male athletes abusing anabolic steroids were suffering
strokes and heart attacks in their 20s (20) and that male rat aortas
were more sensitive to rabbit aorta contracting substance (21),
subsequently shown to be thromboxane A2, and that in laboratory
animals, testosterone pretreatment enhanced thrombogenic
stimuli (22). We hypothesized that testosterone may increase the
expression of TP receptors and in turn is responsible in part for
these observations. This hypothesis was tested in cultured
vascular smooth cells, HEL cells (model for megakaryocytes),
rats and ultimately in normal male volunteers and patients with
prostate cancer. Collectively, these studies demonstrated that in
both pharmacologic doses as well as endogenous levels,
testosterone may regulate the expression of TP receptors (23-26).
Throughout my research career, I have learned many lessons
that help to make one more successful. They are enumerated
below.
Dr. H’s “TOP 10” lessons for success
 Perseverance
 Think out of the box
 Challenge the dogma
 Take risks
 Failure is not a bad thing
 Focus
 Select a good mentor(s)
 Choose your collaborators and colleagues wisely (team
science)
 When you start an experiment-finish it (analyze all the data)
 Take time for your family
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